Bibliography


239
Achieving proof of concept in drug discovery and development


Bibliography


Bibliography

Achieving proof of concept in drug discovery and development


Bibliography

Ivinson, A.I. (2005) University Investment in Drug Discovery. SCIENCE, 310(5749), 777
Achieving proof of concept in drug discovery and development


Bibliography

Klausner, A. (2005) *Mind the (Biomedical Funding) Gap*. NATURE BIOTECHNOLOGY, 23(10), 1217–1218
Lande, R.H. (1988) *The Rise and (Coming) Fall of Efficiency as the Ruler of Antitrust*. THE ANTITRUST BULLETIN, 33, 429
Achieving proof of concept in drug discovery and development


Lee, P. (2012) Transcending the Tacit Dimension: Patents, Relationships, and Organizational Integration in Technology Transfer. CALIFORNIA LAW REVIEW, 100, 1503


Achieving proof of concept in drug discovery and development


Bibliography

Achieving proof of concept in drug discovery and development

Reed, J.C. (2011) NCATS Could Mitigate Pharma Valley of Death. GENETIC ENGINEERING & BIOTECHNOLOGY, 31(10), 6–8
Bibliography


Achieving proof of concept in drug discovery and development


Achieving proof of concept in drug discovery and development

Zambrowicz, B.P. and Sands, A.T. (2003) Knockouts Model the 100 Best-Selling Drugs – Will They Model the Next 100? NATURE REVIEWS DRUG DISCOVERY, 2(1), 38–51

SECONDARY RESOURCES
Almunia, Joaquín (2012) Vice President of the European Commission Responsible for Competition Policy, Industrial and Competition Policy: Quo vadis Europa?, Address at the New Frontiers of Antitrust 3rd International Concurrences Conference (Feb. 10)
American Bar Association’s Section of Antitrust Law, Section of International Law and Section of Intellectual Property Law on Commission Regulation on the Application of Article 81(3) of the EC Treaty to Categories of Technology Transfer Agreements and Commission Notice on Guidelines on the Application of Article 81 to Technology Transfer Agreements (February 2012)
AUTM US Licensing Activity Survey Highlights (FY2011)
Council for American Medical Innovation (CAMI) (2010) Gone Tomorrow: A Call to Promote Medical Innovation, Create Jobs, and Find Cures in America, prepared by the Battelle Technology Partnership Practice, June 10
Bibliography

Directorate General for Internal Policies, Policy Department A: Economic and Scientific Policy (2011) *Differences in Costs of and Access to Pharmaceutical Products in the EU*


EFPIA, *The Pharmaceutical Industry in Figures*, 2010

EFPIA, *Competition Occurs through Successful R&D*

ERC-2015-PoC Call for Proposal for ERC Proof of Concept Grant

EUA 2012 Annual Conference on ‘The Sustainability of European Universities’

Europa Press Release ‘Commission Fines AstraZeneca €60 Million for Misusing Patent System to Delay Market Entry of Competing Generic Drugs’, IP/05/737, 15 June 2005

European Federation of Pharmaceutical Industries and Associations (2012) *The Pharmaceutical Industry in Figures*

European Federation of Pharmaceutical Industries and Associations *Submission to the European Commission in Relation to the Pharmaceutical Sector Inquiry*

Executive Summary of EvaluatePharma World Preview 2013, Outlook to 2018, Returning to Growth


Food and Drug Administration’s Approved Drug Products with Therapeutic Equivalence Evaluations


FT Global Pharmaceutical and Biotechnology Conference on 6 December 2011


House of Commons Science and Technology Committee (March 2013) *Bridging the Valley of Death: Improving the Commercialization of Research, Eighth Report of Session 2012–13*
Achieving proof of concept in drug discovery and development

IMS Health World Review Analyst 2013
King, S. (2014) Firstword Lists – Pharma’s 50 biggest selling drugs, March
OECD Directorate for Financial, Fiscal and Enterprise Affairs, Competition Committee Merger Review in Emerging High Innovation Markets 2003
OECD Health Statistics 2013
OECD Research and Development Database, May 2011
Bibliography

OECD (2009) *Open Innovation in Global Networks*. Organisation for Economic Co-operation and Development
OECD (2010) *Innovation in Firms*. Organisation for Economic Co-operation and Development
Overview of Submissions Received from Stakeholders in the Public Consultation on the Draft Proposal for a Revised Block Exemption Regulation for Technology Transfer Agreements and for Revised Guidelines
Patents and Pharmaceuticals – a Paper given on 29th November at the Presentation of the Directorate-General of Competition’s Preliminary Report of the Pharma-Sector Inquiry
Pfizer 2011 Financial Report
Pharmaceutical Research and Manufacturers of America (2013), *2013 Biopharmaceutical Research Industry Profile*. Washington, DC: PhRMA, July

The Role of Static and Dynamic Analysis in Pharmaceutical Antitrust, at the Fifth Annual In-House Counsel Forum on Pharmaceutical Antitrust (18 February 2010)

Royal Society (March 2011) *Knowledge, Networks and Nations: Global Scientific Collaboration in the 21st Century*


U.S. Food and Drug Administration (2004) *Innovation or Stagnation: Challenge and Opportunity on the Critical Path to New Medical Products*

U.S. Food and Drug Administration Center for Drug Evaluation and Research (2011) *New Molecular Entity Approvals for 2010 Report*, 1 March

Bibliography

Report: The Changing Face of Innovation*, Chapter 4: ‘Harnessing
Public Research for Innovation – The Role of Intellectual Property’
New Record in 2011*, Geneva, PR/2012/703
Medicare Prescription Drug Benefit and Pharmaceutical Innovation.
Manhattan Medical Institute Medical Progress Report, No. 3